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 Hepatitis C virus (HCV) is considered to be the leading cause of hepatocellular 
carcinoma (HCC). During the last years, several highly efficacy regimens of direct-acting 
antivirals (DAAs) with excellent rates of success became available. However, therapeutic 
failure may occur in up to 10% of treated individuals.  
 Our aim was to study the profile of NS5 coding region RASs in DAA-naive 
genotype 1 HCV infected patients, as well as to ascertain an association between 
treatment failure and the presence of baseline NS5 RASs. A comparison between LiPA 
and Sanger sequencing genotyping methods was also assessed.  
 Plasma RNA from 81 DAA-naïve GT1 HCV infected patients was extracted, 
followed by an in-house nested RT-PCR of the NS5 coding region. PCR products were 
purified, leading to Sanger population sequencing on the 3130xl ABI Genetic Analyzer.  
Sequences were aligned using ChromasPro

 v1.7.6, and analyzed online in 
hcv.geno2pheno.org.   
NS5A RASs were present in 28,4% (23/81) of all GT1 infected patients. The most 
commonly detected NS5A RAS was Y93C/H with a prevalence of 9,9% (8/81) in all GT1 
infected patients. NS5B RASs showed a prevalence of 14,8% (12/81) in all GT1 infected 
patients, and were only detected in GT1b, being mainly represented by C316N 
accounting for 40% (10/25). The combined Q30H+Y93H NS5A RASs, were detected at 
baseline in one HIV/HCV GT1a co-infected patient who later failed a treatment with 
sofosbuvir/ledipasvir (SOF/LDV) for 12 weeks. An isolated Y93H mutation was also 
detected at baseline in a relapsing GT1b mono-infected patient. Overall 38,3% (31/81) of 
all GT1 HCV infected patients presented NS5 RASs at baseline, in which 58% (18/31) 
were co-infected with HIV/HCV.  
The obtained data supports the usefulness of resistance testing prior to treatment 
initiation, as a statistical significant association was found between treatment failure and 








 O vírus da Hepatite C (VHC) é considerado a principal causa de carcinoma 
hepatocelular. Durante os últimos anos surgiram diversos regimes de antivirais de 
atuação direta (AADs) com elevada eficácia. Contudo, os insucessos terapêuticos podem 
ocorrer em até 10% dos doentes tratados.  
 O nosso objetivo foi estudar as substituições associadas a resistência (SARs) da 
região codificante NS5 em doentes infetados com VHC de genótipo 1 nunca antes 
tratados com AADs, assim como averiguar uma associação entre o insucesso terapêutico 
e a presença de SARs da NS5. Foi igualmente realizada uma comparação entre os 
métodos de genotipagem por LiPA e sequenciação. 
 O ARN plasmático de 81 doentes infectados com VHC de GT1 foi extraído, 
seguido por um in-house nested RT-PCR da NS5. Os produtos amplificados foram 
purificados, levando à sequenciação de Sanger usando o 3130xl ABI Genetic Analyzer. 
As sequências foram alinhadas usando o ChromasPro
 
v1.7.6, e analisadas online em 
hcv.geno2pheno.org.   
 As SARs da NS5A estiveram presentes em 28,4% (23/81) de todos os doentes 
infetados com VHC de GT1, com a mutação Y93C/H exibindo uma prevalência de 9,9% 
(8/81). As SARs da NS5B demonstraram uma prevalência de 14,8% (12/81) e foram 
apenas detetadas no GT1b. As SARs Q30H+Y93H da NS5A estiveram presentes num 
doente co-infetado com VHC de GT1a e VIH que mais tarde demonstrou um insucesso 
terapêutico perante um regime de sofosbuvir/ledipasvir durante 12 semanas. Uma 
mutação Y93H isolada esteve presente num doente recidivo com VHC de GT1b. De 
modo geral, 38,3% (31/81) de todos os doentes infetados demonstraram SARs da NS5, 
dos quais 58% (18/31) estavam co-infetados com VHC e VIH.  
 Os dados obtidos suportam a utilidade dos testes de resistência basais, tendo em 
conta que foi encontrada uma associação estatisticamente significante entre o insucesso 
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1.1. Epidemiology of Hepatitis C virus 
 Hepatitis C virus (HCV) is considered to be the leading cause of hepatocellular 
carcinoma (HCC) and further co-morbidities such as cirrhosis and other chronic liver 
diseases.  
 A 2013 Global Burden of Disease Study (GBD) described an estimate of 184 
million people positive for anti-HCV antibodies of which 130 – 150 million were 
chronically infected 
1
, and about 704 000 HCV associated mortalities were reported in the 
same year 
2
. More recent data from the GBD 2017 
3
 estimate that about 158 million 
people are seropositive for HCV, being remarkable that China alone accounts for almost a 
third of the HCV global prevalence, namely more than 45 million seropositive people 
(Figure 1.1). The rise of newly and improved HCV screening assays resulting in less 
false-positive results may have been a determinant factor for this lower estimate. 
Moreover, the number of HCV associated mortalities has also seen a decrease over the 
years to about 489 000 reported deaths, of which more than 159 500 were due to HCV 
related liver cancer 
4
.  
 Overall, there is an estimated prevalence of HCV seropositive individuals of 
about 1,51% in Western Europe 
3
, and recent data from Portugal carried out on a 
nationwide population-based cross-sectional study accounting for more than 1 600 
Portuguese individuals, has demonstrated an estimated prevalence of 0,54% 
5
. Having 
into account that the adult general Portuguese population is estimated to be about 8 600 
000 individuals and the prison population is around 15 000, it would be expected that 
approximately 48a780 of the total Portuguese population were anti-HCV positive 
6
. 
However, a 2013 report from the Portuguese Department of Prison Services had showed 
significantly higher prevalences of 15,6% for hepatitis C infection in incarcerated 
individuals only 
6
. Along these lines, there is an underlined low endemicity for hepatitis C 
infection in the general Portuguese population, in contrast to a very high prevalence in 
risk groups such as intravenous drug-users and incarcerated individuals. Furthermore, 
according to the GBD 2017 
3




194500 people positive for anti-HCV antibodies in Portugal (1,96%), which resulted in 
922 HCV associated mortalities back in 2016 
4
, consequently overestimating the results 






Figure 1.1 Worldwide estimated people with anti-HCV antibodies in 2016 (in millions), in 21 GBD 
regions. Data obtained from [3,7].   
1.2. HCV and the Flaviviridae family 
1.2.1. Taxonomy and Baltimore classification 
 Hepatitis C virus of the Hepacivirus genus belongs to the Flaviviridae family. 
According to the Baltimore classification, HCV matches the group IV, meaning that is a 
positive single-stranded RNA virus.  
1.2.2. Virus and virion 
 The RNA genome of HCV is enclosed in an icosahedral capsid surrounded by an 
envelope with 2 types of glycoproteins, E1 and E2. The genome of HCV bears a length of 
approximately 9600bp 
8
 which translates about 3000 amino acids.  
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 The virion presents itself in a spherical form with a diameter of approximately 40 
– 80nm in the blood of the infected patients 
9
. Moreover, in cell culture systems the size of 
the virions may also vary within this range 
10
. 
 Whilst in the blood of the infected patient, HCV presents itself in a unique form of 
lipoviroparticle (LVP), seeing that the low density lipoproteins (LDL) and very low 
density lipoproteins (VLDL) components of this particle are thought to be involved in 
facilitating virus entry into the cell, as well as in immune system evasion 
11
. 
1.2.3. HCV and Flaviviridae 
 Flaviviridae viruses share some similar characteristics amongst themselves, such 
as a lipid bilayer with two or more types of envelope glycoproteins, which surrounds a 
nucleocapsid that encloses the positive single-stranded RNA genome with a length that 
ranges from 9600bp to approximately 12300bp. Moreover, these viruses are known to 
have an ORF which translates at least 3000 amino acids, leading to the encoding of 
structural and non-structural proteins. 
12
 
1.2.3.1. Structural and pathophysiological differences between 
HCV and other flaviviruses 
 While most flaviviruses depend on capping of the 5' region for translation 
initiation 
13
, HCV approach resides in the assembly of an internal ribosome entry site 
(IRES) by folding the 5'UTR into a RNA secondary structure and partially joining it to 
the domain that encodes for the core region. In this way, it´s possible to create a stable 
pre-initiation complex by binding the ribosomal subunits with the cellular factors without 




 On the opposite side of the genome, HCV displays a less structured and relatively 




1.3. HCV replication cycle 




 Hepatitis C virus exhibits a restrict tropism as a result of infecting mainly 
hepatocytes which explains the related hepatic maladies.  
 The first step in HCV replication cycle resides in cell entry through the binding of 
envelope glycoproteins E1 and E2 to the glycosaminoglycans cellular receptors 
15,16
. 
Consequently, the low pH inside the endosomal compartment will induce conformational 
changes in the surface glycoproteins E1 and E2 leading to the fusion of membranes and 
capside internalization into the cytoplasm via a clathrin mediated endocytosis 
17,18
.  
1.3.2. Genome translation and post-translational 
processing 
 The HCV RNA genome located in the cytoplasm after decapsidation is 
recognized by cellular ribosomes as mRNA, being directly translated into a precursor 
polyprotein via IRES domains II to IV 
19,20
. Thanks to a process of post-translational 
maturation in the endoplasmic reticulum, this polyprotein is ultimately cleaved by 
cellular and viral proteases into two structural proteins and eight non-structural proteins. 
 Translation modulation is facilitated by viral (NS2, NS3, NS4A, NS4B) and host 
factors involved in the assembly of ribosomes and in the recognition of 5'UTR IRES 
21–23
. 
Moreover, IRES plays an important role in capping independent translation modulation 
by recruiting viral and cellular proteins, including the initiation factors eIF2 and eEF3 
24,25
. 
1.3.3. Genome replication mechanism 
 HCV genome replication occurs once the amount of viral proteins produced is 
sufficient, and is carried out on the surface of the endoplasmic reticulum (ER) in 
cytoplasmic viral factories i.e. specific intracellular membrane rearrangements 
12,26
.  
 The NS5B viral protein is a RNA-dependent RNA polymerase (RdRp) 
responsible for viral replication by producing copies of negative-sense single strands of 
RNA which in turn will serve as templates for the synthesis of genomic RNA strands 
acting both as mRNA for translation of the polyprotein, synthesis of new intermediates 
for replication, and as genomes for exiting viral particles 
27
. Furthermore, several viral 




of the viral genome by binding the RdRp to the RNA template 
28
, taking into account that 




1.3.4. Virions assembly and release 
 The assembly of the progeny virions occurs in the ER and is facilitated by the viral 
p7 ion channel. The process begins with the relocation of genomic RNA and viral 
proteins to cytoplasmic organelles designated as lipid droplets, and is regulated by both 
viral NS5A and host proteins 
29
. Subsequently, the NS2 viral protein will allow the viral 
capsids to acquire an envelope along with the E1 and E2 glycoproteins through budding 
of the ER membrane 
30
.  
 Finally, the new viral particles will undergo on a maturation process via 




1.4. HCV transmission routes 
 Hepatitis C virus is transmitted exclusively between humans typically by blood 
and/or sexual contact thus demonstrating a narrow specificity for the host. Although the 
risk of HCV transmission via sexual contact is quite real, it is highly reduced in 
heterosexual couples without a pre-existent HIV infection 
32
. Children born to mothers 
with HCV infection are also at risk by exhibiting vertical transmission rates of 
approximately 4 – 8%, which are substantially higher in infants born to HIV co-infected 
mothers, namely 10,8 – 25% 
33,34
, and unlike with HBV and HIV, there are no 
interventions to reduce the risk of vertical HCV transmission during pregnancy 
35
. 
 Since HCV was only discovered in 1989 by means of molecular biology tools 
36
, 
the majority of cases linked to healthcare until then were due mainly to blood transfusions 
without a proper pre-screening test and also to procedures like renal dialyze 
37,38
. 
However, injection malpractices by risk groups denominated as people who inject drugs 
(PWID) have been recently demonstrated to constitute the majority of hepatitis C virus 






1.5. Natural course of HCV infection 
 After exposure to HCV, an incubation period of 2 to 12 weeks leads to an acute 
infection of which only 10 – 15% of the cases are symptomatic. However, 55 – 85% of the 
acute cases can progress to a chronic infection, while the remaining 15 – 45% are capable 
of a spontaneous clearance within 6 months in the absence of any treatment 
40
. 
 Failure to treat the chronic infection may initially lead to morbidities such as liver 
failure and fibrosis, and later to a risk of developing cirrhosis of 15 – 30% in 20 years 
41–43
. Consequently, the risk of developing a hepatocellular carcinoma in patients with 




 Recent data suggests that when comparing to non-treated patients, the risk of HCC 
and other liver morbidities as well as HCV associated mortality are significantly reduced 
the earlier a sustained virological response (SVR) is achieved 
44–46
. 
 The spontaneous clearance of HCV may be associated with host-related factors 
such as race, weight, the female gender, a young age, and polymorphisms in the IL28B 
gene. However, the presence of these criteria cannot guarantee with certainty a 
spontaneous viral clearance in the patient 
40
. 
1.6. HCV genome structure and functions 
 The HCV genome is comprised of two ORFs flanked by the 5' and 3' UTRs. The 
first ORF encodes for the HCV polyprotein which is then cleaved into 10 distinct 
proteins, including 3 structural proteins and 7 non-structural proteins (Table 1.1), 
whereas the second ORF produces the F protein which is thought to be involved in 
immune system evasion 
47
.   
1.6.1. Structural proteins 
 The 5'UTR is of great importance in the capping-independent translation initiation 
of genomic RNA thanks to the action of a secondary structure with four different 
stem-loops termed IRES 
48
. This region comes very useful in HCV genotyping, seeing 




 The 3'UTR-end is a variable region, set up by a poly U/UC and a 3'X region, and 
despite being in the opposite side of the genome this region also plays an important role 




Table 1.1 Hepatitis C virus structural and non-structural proteins. 
 
1.6.2. Non-structural proteins 
1.6.2.1. NS3/4A protease 
 The NS3 gene has a length of 1893bp and encodes for the viral protease with 631 
amino acids and about 69 kDa (Figure 1.2) 
12,50
. 
 NS3 contains a serine protease domain in its N-terminal, while NS4A is a cofactor 
of NS3 protease activity assuming as the helicase domain of the NS3 multi-functional 
protein. Overall, the NS3-NS4A protease is essential for the HCV replication cycle, as it 
catalyzes HCV polyprotein cleavage at the several non-structural proteins junctions, and 





 The NS5A gene has a length of 1344bp and encodes for a phosphorylated 
zinc-metalloprotein with 448 amino acids and about 56 – 58 kDa (Figure 1.2) 
12,51
. 
 NS5A consists of three domains and does not exhibit any enzymatic activity. 
However, it plays an important role in the assembly and release of virions (domain III) as 
well as in viral replication (domains I and II), namely in transcription activation 
52,53
.  
 The NS5A complex is also involved in the regulation of cellular pathways by 
demonstrating several interactions with host proteins, and plays an additional role in 
immune system evasion, namely in the resistance to IFN-α via binding and blocking of 
the antiviral effector PKR 
54,55
.  
1.6.2.3. NS5B polimerase 
 The NS5B gene has a length of 1773bp and encodes for a protein with 591 amino 
acids and about 68kDa, corresponding to the RdRp (Figure 1.2) 
12,56
. The NS5B 
polymerase belongs to a class of membrane proteins 
57,58
 and is structurally arranged in a 
"right hand motif" containing palm and thumb domains 
59
. Moreover, it plays an 




Figure 1.2 Hepatitis C virus genome and polyprotein structure, flanked by the 5' and 3' UTRs 
consisting of IRES and a poly U (U/C) tract, respectively. 
1.7. High genetic variability of HCV and its 
implications 




currently divided into 7 genotypes and more than 80 known subtypes. However, current 
therapeutic regimens are only designed for genotypes 1 – 6 since genotype 7 is of less 
clinical relevance 
61,62
. In this way, each genotype and subtype of HCV is associated with 
a geographic location, transmission risk, the prevalence and level of genetic diversity 
63
, 




 The high genetic variability of HCV can first be explained over the NS5B 





per copied nucleotide) 44, and to the enormous viral turn-over (1010 – 1012 virions per day) 
65–67
 about 100x superior to HIV 
68
, hence why HCV replicates as a population of 
quasispecies i.e. a heterogeneous mixture of closely related genomes with a homology 
superior to 98% which may be present in the same individual 
69
. 
The genetic barrier to resistance is of major importance when dealing with the 
high genetic variability of HCV in treatment selection, since it is assumed as the number 
and type of nucleotide changes required to result in amino acid substitution(s) that confer 
resistance to the antivirals 
70
, and may vary both within and between the classes of DAAs 
according to the genotype and subtype of HCV 
71,72
.  
1.7.1. HCV geographic distribution 
 Genotype 1 is the most prevalent, globally accounting for 83,4 million (46,2%) of 
all HCV infections, while HCV GT3 constitutes the second most common with 54,3 
million (30,1%) cases worldwide, followed by genotypes 2, 4, 6 and 5 accounting for 
16,5 million (9,1%), 15 million (8.3%), 9,8 million (5.4%) and 1,4 million (<1%) of the 
cases, respectively 
73
. As such, treatment is immediately recommended after confirming a 
GT1 HCV infection 
41
. 
 It is notable that genotypes 1 and 3 seem to have a worldwide geographic 
distribution as well as genotype 2 to some extension, while genotype 4 appears to be 
mainly found in central sub-Saharan Africa and Middle East (Figure 1.3). Genotypes 5 
and 6 are restricted to Southern sub-Saharan Africa and Southeast Asia, respectively. 
In Portugal, just like at the global level, GT1 is the most prevalent accounting for more 
than 60% of all HCV infections in Portugal, whereas GT3 occupies the second place with 










Figure 1.3 Worldwide predominance of HCV genotypes in 21 GBD regions. HCV genotypes 1a 
and 1b are shown in red just as HCV genotype 1, though additionally differentiated as stripes or 
dots to indicate the prevalent subtype, respectively. Countries and/or GBD regions in which no 
data was reported are visualized as grey. Data to construct this map was obtained and adapted 
out of extensive literature research dating from 2013 to 2017 
73,75–79
. 
1.8. Screening of HCV infection 
 Screening for HCV infection should start with a serological test in order to detect 
anti-HCV antibodies, and if positive is followed by a nucleic acid test (NAT) to search for 
HCV RNA so confirming the diagnosis of an active infection 
41,80
. The NAT is based on a 
sensitive molecular method, and as the presence of anti-HCV antibodies only 
demonstrates that there has already been a past exposure to the virus it becomes thus 
indispensable for the confirmation of the chronic infection, since there are no serological 
markers that prove that HCV infection is in an acute phase acquired de novo 
40
. When 
quantitative HCV RNA tests are not available or accessible, a recommended alternative is 
the measurement of the HCV core antigen levels by means of an enzyme-linked 















 The diagnosis of acute HCV infection is performed through an EIA and can only 
be confirmed with certainty when a seroconversion of the anti-HCV antibodies is 
achieved. Moreover, the EIA may turn out negative when performed during an early 
acute infection or when in patients on a profound immunosuppressive state 
83
.  
 HCV re-infection is much less common than relapse but not less severe, as it tends 
to occur essentially in patients at a high risk of infection following spontaneous HCV 
elimination or after an induced treatment. Re-infection is defined as the reappearance of 
HCV RNA in the blood at least 6 months after a SVR is achieved, having to demonstrate 
simultaneously that the new infection is caused by a different strain of HCV. This can be 
confirmed when the new strain belongs to a different genotype, or if identical, through 
phylogenetic analysis by checking the genetic distance between the strains in question 
40
. 
1.9. Genotyping HCV: a prognostic tool for treatment 
selection 
 HCV genotyping before treatment initiation is currently mandatory to assist 
physicians in the selection of the most appropriate IFN-free regimen for each specific 
case 
40
. Although some next-generation DAAs already exhibit a pan-genotypic activity, 
most of the precedent drugs did not demonstrate an equal antiviral activity between all 
genotypes or even subtypes 
84,85
, and as such the correct assignment of the HCV genotype 
is necessary in order to reduce the risk of therapeutic failure 
86
.  
 It is well known that HCV genotypes/subtypes play an important role in the 
response to treatment 
87
, and several phase III studies 
88–91
 have demonstrated that 
intra-genotypic SVR rates in GT1 are generally lower for GT1a than for GT1b according 
to the selected regimen, subtypes prevalence and to the presence of RASs. However, 
when mentioning sofosbuvir (SOF) the situation is reversed, seeing that lower SVR rates 
were observed on treatment-naïve (TN) patients infected with GT1b HCV 
92
. The HCV 
subtyping of GT1a and GT1b should employ a highly accurate test using the 5'UTR with 
the partial addition of another genomic region, usually the core or the NS5B 
40,93
. 
 In the case of mixed infections by different HCV genotypes, only one of them 
prevails and their impact on potential RASs and SVR rates when using DAAs regimens 
should be considered 
94








1.9.1. HCV genotyping assays 
 Several commercial assays are currently available to assign the HCV genotype, 
most of which are oriented to the well characterized and highly conserved 5'UTR. 
However, since the single use of this genomic region proved to be insufficient for the 
correct genotyping of all HCV strains 
96
, the two most frequently used tests are "Abbott 
Real-time HCV Genotype II" and "INNO-LiPA HCV Genotyping 2.0", which are further 
directed to the NS5B and core genes, thus providing additional subtype information 
97
. 
Nonetheless, even with the use of increasingly accurate and rigorous genotyping tests, it 
is common to have indeterminate, unspecific, mixed or invalid cases due to low viral 
loads, sample inhibitions or even to unknown factors, and under these circumstances 
genotyping by sequencing can constitute an alternative approach when traditional 
methods do not work. 
1.9.2. HCV genotyping by sequencing the NS5B gene 
 NS5B sequencing allows an accurate genotyping of HCV, as 53 – 55% of this 
gene amino acids are conserved amongst all HCV genotypes 
98,99
. In addition, a portion of 
the NS5B gene with 329bp, named Okamoto region (from nt 8282 to 8610 in the H77 
reference genome) becomes particularly useful in HCV genotyping for its ability to 
subtype with a higher level of discrimination, as well as to represent the entire genome of 
HCV. Moreover, sequencing data obtained from the Okamoto region can lead to the 
construction of more accurate phylogenetic trees regarding whole-genome and/or 
polyprotein analysis, when comparing to data obtained from the 5'UTR 
100
.   
 Recent studies suggest that the use of the NS5B region may be preferential to the 
5'UTR when genotyping by sequencing 
101,102
. Moreover, sequencing becomes an added 
value since it is able to provide additional information on the resistance profile for each 








 Although NS5B sequencing costs may vary according to each commercial 
platform and technique, this technique not only allows a very accurate genotyping of 
HCV but also prevents future therapeutic failures by giving an insight of potential RASs 
that may be present at baseline prior to treatment initiation.  
1.10. Antiviral therapies for HCV infection 
1.10.1. Treatment of HCV acute infection 
After exposure to HCV, patients are associated with high rates of chronicity, so a 
treatment should be followed in order to prevent a chronic hepatitis C infection 
40
. 
There is currently no antiviral therapy indicated for post-exposure prophylaxis in 
the absence of a documented HCV transmission 
40
. Along these lines, the ideal estimated 
starting point for acute hepatitis C treatment is based at the onset of alanine 
aminotransferase (ALT) elevation, with or without symptoms 
103,104
, and should use the 
recommended combination of SOF + LDV for genotypes 1, 4, 5 and 6, or SOF + VEL or 
SOF + DCV for all genotypes, during a period of at least 8 weeks without RBV 
40
. 
A small number of patients with acute GT1 HCV infection were treated with an 
IFN-free regimen based on SOF + LDV, exhibiting SVR rates of 93% (13/14) in 
mono-infected IVDU after 4 weeks of treatment, SVR rates of 77% (20/26) in HIV/HCV 
co-infected patients after 6 weeks of treatment 
105
, and SVR rates of 100% in 
mono-infected non-IVDU after 6 weeks of treatment 
106
. As such, patients co-infected 
with HIV and acute HCV should be treated with the same recommended regimens for 
HCV acute mono-infection but for an extended period of 12 weeks 
40
. 
1.10.2. Treatment of HCV chronic infection 
The primary goal of HCV treatment is to achieve a SVR, which is defined as an 
undetectable viral load in the blood 12 (SVR12) or 24 (SVR24) weeks after the end of 




The secondary goal of HCV treatment is achieved through a SVR and is 
associated to the prevention and reversion of HCV related hepatic and extrahepatic 






clearance following SVR not only is also associated with the normalization of liver 
enzymes and liver failure reduction, as well as with a decreasing risk of HCC, all-cause 
mortality and other comorbidities, although to a lesser extent regarding HIV/HCV 
co-infected patients, but also comes with other more personal and even economical 
advantages such as an improved quality of life and work productivity 
40,108–110
. 
SVR12 and SVR24 should be evaluated through a sensitive molecular method 
with a low limit of detection (LOD) (≤ 15 IU/ml) 
40
. However, an undetectable HCV core 
antigen after the end of treatment (EoT) may also be used as an alternative to HCV RNA 
screening, when in patients with a detectable core antigen before treatment initiation 
111
.  
1.10.3. Advancement of therapy options 
Prior to 2011, the only therapeutic options for HCV chronic infection were based 
on a combination of pegylated interferon-α (pegIFN-α) with ribavirin (RBV) for 24 – 72 
weeks. However, this therapy was associated with severe adverse effects and low SVR 
rates of 30 – 70% 
112,113
 ranging between mono-infected and HIV/HCV co-infected 
patients, according to the IL28B polymorphisms and to the HCV genotype, the last being 
the most relevant predictor of treatment outcome 
114
. 
Since 2014, IFN-free regimens constitute the best treatment options in chronic 
hepatitis C infection for TN and treatment-experienced (TE) patients with compensated 
or decompensated liver disease as a result of the ease of use through all-oral DAAs, 
increased tolerability showing fewer adverse effects, the lower presence of potential 
RASs and mainly due to the dramatic increase in viral suppression demonstrating SVR 
rates above 90% 
40,76,88,115–117
. 
Although DAAs have been shown to be more effective in viral suppression when 
compared to IFN-based regimens, they are still not 100% effective, namely due to low 
adherence to treatment and factors related to the progression of liver disease (e.g. 







1.10.4. Direct-acting antivirals 
There are currently approved four classes of DAAs aimed for the non-structural 
proteins NS3/4A, NS5A and NS5B (Table 1.2). Each class varies in efficacy according to 
the virological response rates, adverse effects, drug-drug interactions, the genotype of 
HCV, and to potentially associated RASs 
84,118
. As such, the current treatment strategies 
consist of developing pipeline DAAs with a pan-genotypic activity, in addition to an 
increasingly potency in order to avoid future relapses. 
Table 1.2 Licensed direct-acting antivirals (DAAs) since 2011 and associated sites of action. 
DAAs respective abbreviations are in parenthesis.  
 
Since the transmission routes of HIV, HBV and HCV are identical, it’s not 
unusual to see these co-infected patients being treated simultaneously for both infections, 
however if so it must be done with caution since the large multiplicity of HCV antivirals 
can lead to potentially complex drug-drug interactions. Along these lines, all patients 
selected for a therapy with DAAs require a risk assessment of drug-drug interactions prior 
to treatment initiation 
40
. 
1.10.4.1. NS5A inhibitors 
Although the NS5A inhibition mechanism is yet to be fully elucidated, it basically 
consists on an interaction between the inhibitors and the domain I of the dimer 
53
. 




compared to the first generation precedents, though not as high as the nucleoside 
inhibitors (NIs) of the NS5B polymerase 
119
. Moreover, pipeline NS5A inhibitors have 
been increasingly displaying a more comprehensive coverage for all HCV genotypes, as 




1.10.4.2. NS5B polymerase nucleoside inhibitors 
RdRp is yet another important target to consider in the development of advanced 
HCV antivirals 
12,121
. NIs act via mimicking of the natural substrates which are 
incorporated into the elongating RNA strand, thus interacting directly with the active site 
of the polymerase, and ultimately ending the RNA elongation mechanism 
102,118
.  
NIs possess the highest genetic barrier to resistance of all DAA classes, not only 
because the associated NS5B RASs have a low probability of existing at baseline, but 
also because these inhibitors require at least three or more nucleotide changes and/or 
transitions in order to confer a resistance associated mutation 
118,122,123
. Several studies 
have additionally demonstrated the relevant pan-genotypic activity of NIs, mainly due to 




Sofosbuvir was approved in the USA and in Europe back in 2013 and 2014, 
respectively 
125,126
, and possesses a pan-genotypic antiviral activity 
98
 along with a high 
genetic barrier to resistance 
127
, which has been fully tested in several clinical trials which 
demonstrated the absence of RASs through viral breakthrough both in monotherapy and 
combination regimens with other recommended DAAs 
117,128–130
, thus proving that the 
majority of NS5B RASs are indeed of relatively low importance 
129,130
. 
A large phase III study back in 2013 
92
, demonstrated the high efficacy of a SOF 
monotherapy with pegIFN-α + RBV in GT1 infected patients whom never experienced 
treatment, by exhibiting a SVR rate of 89%. However, as the safety and pharmacokinetics 
of the metabolites derived from SOF are still being studied, this drug should be used with 






1.10.4.3. NS5B polymerase non-nucleoside inhibitors 
Non-nucleoside inhibitors (NNIs) suppress the NS5B polymerase activity via 
mechanisms of allosteric inhibition, and can be subclassified according to their allosteric 
binding sites (Palm 1, Palm 2, Thumb 1, and Thumb 2) 
131
. Furthermore, NNIs possess a 
low genetic barrier to resistance when comparing to NIs 
119
. 
1.10.5. Selection of genotype-dependent therapies 
1.10.5.1. Sofosbuvir and ledipasvir combined regimens 
 The regimen of harvoni (combined fixed dose of SOF and LDV in a single tablet, 
represented as SOF/LDV) for 12 weeks, with or without ribavirin, is one of the preferred 
therapies recommended for the treatment of DAA-naïve patients infected with GT1 
HCV, with or without compensated cirrhosis (Table 1.3). However, this regimen should 
be extended to 24 weeks without RBV, when in patients with contraindications or low 
tolerance for RBV 
40
. 
 Due to the high rates of SVR (> 96%) as well as higher adherence rates over the 
improved safety both on TN and TE patients, a treatment with SOF/LDV ± RBV is 




 It has been demonstrated that only high risk RASs appear to have an impact on the 
response to treatment 
132
, when exposing an HCV infected patient to an IFN-free therapy 
based in SOF/LDV ± RBV for 12 weeks. Along these lines, optimal SVR rates of 94 – 
97% were reported in several clinical trials directed for TN and TE patients infected with 
GT1 HCV 
117,129,130
, additionally with no decrease in the SVR rates even when patients 
had an advanced liver disease status 
133
. 
 A combined regimen of SOF + LDV for the treatment of GT1 HCV infection has 
been proven to be efficient by exhibiting high SVR rates in several clinical trials: 
 In the ION-1 clinical trial 129, a 12 weeks regimen with SOF + LDV, with or 
without RBV, was submitted in TN patients infected with GT1 HCV, leading to 
SVR12 rates of 97% (211/217) and 99% (211/214), respectively, even though 




When treatment was extended to 24 weeks, SVR12 rates were of 99% (215/217) 
and 98% (212/217), with or without RBV, respectively, including the cirrhotic 
and non-cirrhotic patients for both treatment extensions.  
 In the phase III ION-2 clinical trial 117, a 12 weeks regimen of SOF + LDV, with 
or without RBV, was submitted alternatively in patients previously treated with 
pegIFN-α ± RBV or a regimen with protease inhibitors (PIs), leading to slightly 
lower SVR12 rates of 96% (107/111) and 94% (102/109), respectively. When 
treatment was extended to 24 weeks, the SVR12 rates went up to 99%, with or 
without RBV, respectively, having increased significantly for both cirrhotic and 
non-cirrhotic patients.  
 For the phase III ION-3 study 130, a SOF + LDV regimen was compared for 
extensions of 8 vs. 12 weeks in 647 non-cirrhotic TN patients infected with GT1 
HCV, leading to SVR12 rates of 93% (201/216) and 94% (202/215) for 8 weeks 
with or without RBV, respectively, vs. 95% (206/216) for 12 weeks without RBV, 
proving that although this shorter in duration regimen isn´t so efficient as a 12 
weeks extension, it can still be performed with a high success rate in non-cirrhotic 
TN patients with baseline HCV RNA levels < 6 million IU/ml (as determined by 
Roche Cobas Taqman HCV assay). Furthermore, it was also reported that the 
presence of any baseline NS5A RASs was not associated with any relapses. 
 In the SOLAR-1 134  and SOLAR-2 135 studies, a combined regimen of SOF + 
LDV with RBV was submitted alternatively for 12 and 24 weeks in patients 
infected with GT1 and GT4 HCV, whom exhibited an advanced stage of liver 
disease or recurrence post liver transplantation, demonstrating high rates of 
SVR12 up to 100% and 94% for GT1 and GT4, respectively. 
 In the phase II SIRIUS clinical trial 136, patients with compensated cirrhosis 
infected with GT1 HCV, whom had previously failed a treatment with PIs, were 
then treated with a fixed dose of SOF + LDV without RBV for 12 or 24 weeks, 
achieving SVR12 rates up to 96% (74/77) and 97% (75/77), respectively. 
 In the phase IIb ERADICATE study 
137
, a fixed regimen of SOF + LDV for 12 
weeks was submitted in non-cirrhotic TN patients co-infected with HIV and GT1 
HCV, leading to SVR12 rates of 97% (36/37) and 100% (13/13), when on or off 




Table 1.3 Efficacy of current valuable IFN-free treatment regimens approved in Europe since 
2013, according to HCV genotype. DAAs based regimens highlighted in green represent optimal 
efficacies corresponding to SVR rates ˃ 90%, whereas the ones marked in orange represent 
suboptimal efficacies corresponding to SVR rates of 75 – 90%. Combined regimens highlighted in 
red are currently not approved due to low efficacies < 75% or insufficient in vivo data. Data 
adapted and gathered from [40,79] and [138–140], respectively. All DAAs are indicated by their 
abbreviations, and DAAs combinations commercial designations are in parenthesis.  
*DAAs already licensed and approved in Europe, but still in development.   
In a recent Portuguese prospective study, 113 cirrhotic GT1 – 4 HCV patients 
co-infected with HIV (77% accounting for GT1) were treated with SOF/LDV ± RBV or 
other regimens, achieving SVR12 rates of 93,8%, ultimately resulting in a significant 
improvement of hepatic function 
141
. 
Another Portuguese study comparing the efficacy of therapies with DAAs 
between 103 HCV mono-infected and 261 HIV/HCV co-infected patients, with or 




co-infected patients (52,4% vs. 75,9%, for mono-infected and co-infected patients, 
respectively), whereas GT3 was higher in HCV mono-infected patients (32% vs. 11,1%, 
for mono-infected and co-infected patients, respectively), and therapies mostly included 
SOF + LDV for 73,8% and 87,4% of mono-infected or co-infected patients, respectively, 
but alternative regimens based in SOF + DCV, pegIFN + SOF or 3D therapy 
(OMB/PTV/Ritonavir + DSV) were also used, resulting overall in SVR rates of 95,1% vs. 
94,6% for mono-infected and co-infected patients, respectively 
142
. 
1.10.5.2. Sofosbuvir and velpatasvir combined regimens 
SOF and VEL are currently available in a single tablet fixed-dose combination 
named epclusa (represented as SOF/VEL). Several studies have already described the 
high efficiency of epclusa for 12 or 24 weeks in HCV infected patients, with or without 
cirrhosis, and when comparing to harvoni it is associated to higher SVR rates with the 
additional advantage of a pan-genotypic activity, thusly being a preferential first-line 
treatment option recommended by EASL 2016 guidelines for patients infected with 
genotypes 1 through 6 (Table 1.3) 
40
. 
A joint analysis over the therapeutic efficacy of epclusa-based regimens revealed 
high SVR rates for all HCV genotypes 
143
 regardless of the presence of a co-infection 
with HIV, cirrhosis status, or the patient´s therapeutic history 
144
. Thusly, a combined 
fixed dose of SOF + VEL without RBV for 12 weeks is recommended for the treatment of 
both TN and TE patients, with or without compensated cirrhosis 
40
. 
The pan-genotypic efficacy of a fixed regimen of SOF + VEL has been 
demonstrated throughout the ASTRAL clinical trials exhibiting high rates of SVR: 
 The combined fixed dose of SOF + VEL was firstly tested on the phase III 
ASTRAL-1 clinical trial 
145
 in which 328 of 624 patients infected with GT1 HCV 
(68% TN, 32% TE, 28% DAA-experienced, and 19% with compensated 
cirrhosis) were treated for 12 weeks without RBV, achieving SVR12 rates of 98% 
(206/210) and 99% (117/118) in patients infected with GT1a and GT1b, 
respectively. 
 In the ASTRAL-4 146 the authors evaluated the efficacy of this regimen for 12 




cirrhosis, achieving SVR12 rates of 94% and 100% in patients infected with GT1a 
and GT1b, respectively. 
 The fixed dose of SOF + VEL was later tested in HIV/HCV co-infected patients in 
the ASTRAL-5 clinical trial 
147
, on which 78/106 TN and TE patients infected 
with GT1 HCV, with or without cirrhosis, were treated for 12 weeks without 
RBV, achieving SVR12 rates of 95% (63/66) and 92% (11/12) in patients infected 
with GT1a and GT1b, respectively. 
 In the ASTRAL-2 and ASTRAL-3 clinical trials 148, the authors compared 
treatments based on SOF + RBV vs. regimens based on SOF + VEL, leading to 
SVR12 rates of 94% vs. 99%, and 80% vs. 95 %, in patients infected with GT2 
and GT3 HCV, respectively, thus demonstrating the superior efficacy of an 
epclusa regimen over the precedent monotherapy options. 
 
1.11. Confronting HCV drug resistances 
1.11.1. Resistance-associated substitutions 
 RASs consist of polymorphisms in the target amino acids of the antivirals, leading 
to a suboptimal therapeutic efficacy with DAAs, which in turn makes the viruses less 
susceptible to its inhibitory activity 
149,150
. 
 RASs can be organized according to a number of factors, either by the associated 
class and HCV genotype (Table 1.4), the level of reduced susceptibility in vitro, the limit 
of detection for every sequencing method, or even regarding their impact on SVR rates 
151
. 
1.11.2. Origin of RASs in the resistance to DAAs 
 The presence of RASs associated to a reduced susceptibility to DAAs can be  
essentially explained by a couple of factors critical to the HCV replication cycle, namely: 
 The high turn-over of HCV, exhibiting a replicative potential of 10101–11012 virions 















Table 1.4 Clinically relevant NS5 resistance-associated substitutions commonly detected at 
baseline in GT1 HCV infected patients. The number corresponds to the position on the gene, and 
the letter preceding the number is the wild-type amino acid, whereas the subsequent letter(s) are 
the amino acid substitution(s) at that position that are associated with NS5A or NS5B inhibitors 




Most RASs are produced at baseline during the viral cycle, and several in vitro 
studies have estimated that whenever a new wildtype HCV is generated there is a 91% 
probability of presenting a non-mutated genome, 8,7% of carrying a single substitution, 
0,4% of carrying two substitutions, and 0,013% of carrying three substitutions 
66
. 
Moreover, it is conceivable that up to 20% of the viral populations may exhibit these 





 resistance-associated variants (RAVs) with a single 
or double mutation, respectively 
66
. However, RAVs can act differently in vitro or in vivo, 
and as such the resistance analysis results should always be interpreted within a clinical 
context, independently of the consequent theoretical changes to the EC50 and EC90 when 
RASs are detected 
159
. 
The emergence of RASs in a treatment based with DAAs is essentially associated 





 At the viral level, the frequency and prevalence of RASs are associated mainly 
with the in vivo viral fitness 
70
, the type of nucleotide changes capable of 
generating a resistance associated mutation 
119
, the potential viral breakthrough 
turning these RAVs into the dominant strains present in the patient 
113
, the 
simultaneous occurrence of compensatory or secondary mutations which in turn 
allows for a more effective replication of the mutant variant 
122
, and finally to the 
genotype as well as to the fitness cost since these RAVs normally have a lower 




 From a pharmacological point of view, the genetic barrier to resistance of DAAs 
is perhaps the most important component involved in the presence of RASs, 
however, the level of exposure to the drug, their potency and pan-genotypic 
activity are all equally important factors to consider 
70,72,123
. 
 At the host level, the presence of RASs is mainly associated to the immune 
response, the fibrosis level and hepatic disease progression 
149,161
, the drug 
distribution to target cells, CD8
+
 T cell depletion due to a continuous exposure to 
the virus 
162,163
, relapse from a previous treatment 
124
, and even due to genetic 




1.11.3. Clinical impact of baseline RASs 
Recent studies have described a prevalence of baseline RASs in HCV infected 
patients that can range from 1 – 80% 
164
 leading to a decrease in SVR rates between 1 – 
50% 
164,165
, according to the genotype of HCV 
124,166
, the selected regimen of DAAs 
124
, 
and the patient´s therapeutic history, as well as the level of liver disease 
165
. Although the 
prevalence of RASs is variable with a level of resistance depending on relatively few 
highly specific but high risk mutations for the NS3, NS5A and NS5B regions, their 




It has been shown in the ION clinical trials 
117,129,130
 that reduced rates of SVR 
observed after a regimen of SOF + LDV for 12 weeks in patients infected with GT1 HCV 
are essentially associated with the presence of baseline NS5A RAS, which conferred an 






Table 1.5 Fold-changes in EC50 of NS5A inhibitors according to clinically relevant NS5A 
resistance-associated substitutions in GT1 HCV. Combinations between RASs and DAAs 
highlighted in red are more likely to result in treatment failures due to the high fold-changes, 
whereas combinations marked in orange tend to demonstrate intermediate fold-changes but still 
having an impact on therapy efficacy. RASs highlighted in shades of green represent very low or 
negative fold-changes associated with resistance to NS5A DAAs and are not likely to have any 
clinically significant impact. NA, data not available. Data adapted from [79,151]. 
* Investigational pipeline direct-acting antiviral 
1.11.3.1. Resistance to NS5A inhibitors 
NS5A constitutes the most important genomic region considered for the screening 
of associated clinically relevant RASs, as it displays the highest number of mutations in 
GT1 HCV 
151
. Moreover, the NS5A associated RAVs are capable of persisting for at least 
one or two years after a therapeutic failure while maintaining the same viral fitness, and in 
this way exhibiting a negative impact on a retreatment regimen with NS5A inhibitors 
89,168–170
. 
Q30H and Y93H are high level transversion mutations which confer a high 
replicative fitness in GT1a RAVs 
71,123,171
, and although the presence of only one of these 




and consequently to a decrease in SVR rates, the synergistic combination of more than 
one of these mutations may be associated with a substantial resistance, such as Q30R + 
Y93H/N which often leads to high in vitro EC50-fold resistance (˃ 1000x) to NS5A 
inhibitors when comparing to the wildtype replicon (Table 1.5) 
164,172,173
. 
1.11.3.2. Resistance to NS5B polymerase inhibitors 
Overall, regimens based on NS5B polymerase inhibitors, particularly NIs, tend to 
exhibit a low prevalence of baseline RASs 
174
, and the S282T mutation although very 
relevant in therapeutic failures after a treatment with NIs, is rarely detected at baseline 
149
. 
Along these lines, NS5B RASs tend to occur more easily after a treatment based on NNIs 
since these drugs bind to the viral polymerase allosteric sites thus presenting a lower 
genetic barrier to resistance 
98
. 
The S282T mutation confers a high level of resistance to sofosbuvir, however, its 
natural presence in the daily clinical practice is very rare 
149
 due to the reduced replicative 
fitness of the viral variants that possess this mutation, which may also explain why a viral 
breakthrough for this RAS is rarely detected during a treatment with sofosbuvir 
113
. 
Moreover, even recurrent patients whom present the S282T mutation after the EoT with 
sofosbuvir, are usually able to quickly eliminate this mutation right after a few weeks thus 
achieving a complete viral suppression 
149,175–177
.  
1.12. What happens when treatment fails 
1.12.1. Management and importance of RASs in treatment 
failures 
RASs are not detected in all recurrent patients since therapeutic failure for a 
regimen with DAAs is additionally related to other factors associated with a poor 
response such as the progression of liver disease, the patient´s therapeutic history, the 
viral load, the efficacy and potency of each DAA, as well as with the genotype of HCV 
113
. However, therapeutic failure rates associated with the use of DAAs may range from 5 
– 10%, mostly being due to the presence of RASs 
161,164,178
, which can occur essentially as 
a post-treatment recurrence with detection rates between 53  – 91% 
70,132,179
, or 
occasionally as a viral breakthrough during treatment 
161




importance consequently increases in rescue therapies after virological failure with a 
suboptimal regimen based on DAAs 
164
.  
The best way to avoid a therapeutic failure associated to the occurrence of RASs is 
to achieve a complete viral suppression right with the first selected therapeutic regimen, 
by using a combination of potent DAAs with a high genetic barrier to resistance, a 
pan-genotypic activity, and preferentially without any cross-resistances 
161
. 
1.12.2. Retreatment guidelines in HCV mono-infected 
patients 
Retreatment should be guided through the patient´s therapeutic history, the 
experience of the team treating the infected patients, and additionally by the potential 
response to a new retreatment regimen according to the obtained resistance profile 
40
, 
assuming that a resistance test is available to perform which can help physicians to better 




According to EASL recommendations on the treatment of hepatitis C 
40
, patients 
infected with HCV whom failed a previous IFN-free treatment, should be retreated with a 
combined regimen of DAAs including a NI with a high genetic barrier to resistance 
(currently SOF), with the addition of one to three other DAAs, ideally without any 
cross-resistances considering the previous submitted treatment, for a period of 12 weeks 
with ribavirin. The retreatment regimen can be extended to a period of 24 weeks with 
RBV when a high level of hepatic disease progression is verified, or alternatively for 24 
weeks without RBV when there is contraindications for its use.   
Several studies have demonstrated the efficacy of IFN-free regimens in the 
retreatment of GT1 HCV infected patients, by exhibiting SVR rates above 97%: 
 Sixty-nine HCV infected patients whom failed a prior treatment with SOF + VEL 
for 12 weeks in previous phase II trials (NCT01858766; NCT01909804; 
NCT01826981; NCT02202980) were retreated with the same regimen plus RBV 
for an extended period of 24 weeks, achieving SVR12 rates of 97% (36/37), 93% 




the retreated GT1 infected patients exhibited NS5A RASs at baseline, of which 
the SVR12 rates were of 100% 
181
. 
 Fifty-one GT1 HCV infected patients whom failed a prior treatment with SOF + 
RBV with or without IFN-α in previous phase II/III trials [P7977-0221 
(NCT01054729); QUANTUM (NCT01435044); PROTON (NCT01188772); 
ATOMIC (NCT01329978); NEUTRINO (NCT 01641640)] were retreated with a 
regimen of SOF + LDV plus RBV for 12 weeks, achieving SVR12 rates of 98% 
(50/51). Moreover, the only patient who didn’t manage to achieve a SVR was a 
GT3a infected patient previously incorrectly identified as GT1a 
182
. 
 In the QUARTZ-1 trial 183, 22 GT1 infected patients whom failed a prior IFN-free 
treatment, were retreated with a regimen of OBV/Ritonavir-boosted PTV + DSV 
+ SOF for 12 or 24 weeks, achieving SVR12 rates of 93% (14/15) and 100% (7/7), 
respectively. Moreover, 82% (18/22) of the retreated patients exhibited baseline 
RASs for at least one of the four main classes of DAAs.  
 
1.12.3. Retreatment guidelines in co-infected patients 
High rates of HIV/HCV co-infection have been reported over the last years due to 
the similar routes of transmission between both viruses, as well as to existence of risk 
behavior groups like PWID 
41




Since DAAs-based regimens have shown again and again a high virological 
efficacy, as well as ease of use and tolerability, the indications for an IFN-free treatment 
of HCV mono-infected patients remain identical to those patients co-infected with HIV, 
HCV and/or HBV, with or without an indication for transplant. However, HIV/HCV 
co-infected patients have an additional risk of exhibiting drug-drug interactions and thus 
may require some treatment changes or dose adjustments when necessary 
40
. 
Although the IFN-free treatment with SOF/VEL is currently highly recommended 
over its potent pan-genotype activity and high SVR rates, there are still some potential 
drug-drug interactions to consider when submitting this regimen in HIV/HCV 
co-infected patients, and in this way should not be given in conjunction with several 




antagonistic reactions as well as consequent adverse effects on the host 
40
. 
In HCV/HBV co-infected patients, HCV normally leads the activity of chronic 
hepatitis B since the DNA levels of HBV are frequently low or even undetectable in this 
co-infection circumstance. As such, patients selected for the treatment of chronic 
hepatitis C with a DAAs based regimen should also be tested for the HBs antigen as well 
as to the anti-HBc and anti-HBs antibodies, in order to thoroughly evaluate the replicative 
state of HBV, and along these lines an HDV infection should be additionally sought 
40
. 
1.12.4. Retreatment guidelines in HCV infected patients 
with an indication for transplant 
The recurrence of hepatitis C after transplantation of an infected organ is universal 
in the absence of treatment, which can lead to a reduction in the average durability of the 
transplant and consequently to the patient´s decease. 
185
. Along these lines, all HCV 
mono-infected or HIV/HCV co-infected patients presenting decompensated cirrhosis 
(Child-Pugh B or C) should be treated with IFN-free regimens based on DAAs, 
regardless if in a pre-transplantation or post-transplantation indication 
40
. This approach 
is supported by several studies describing the virological efficacy, ease of use and safety 
of combined regimens of SOF with an NS5A inhibitor in the retreatment of hepatic 
transplant patients, thus achieving high rates of SVR 
186–188
, not to mention that these 
DAAs do not require any dose adjustments of immunosuppressive drugs 
40
. 
HCV recurrence in renal transplanted patients has been systematically associated 
with several co-morbidities such as an increased rate of cystic fibrosis progression, renal 
graft failure to function correctly, as well as a reduction in survival rates, particularly in 
cirrhotic patients. As such, these patients should be retreated with IFN-free regimens 
following the same recommendations for hepatic transplant recipients 
40
. 
Several studies have demonstrated the high and fast virological efficacy, ease of 
use and tolerability of an IFN-free retreatment in HCV recurrent renal post-transplant 
patients, thus achieving high rates of SVR12. Along these lines a regimen based in DAAs 







1.12.4.1. Treating HCV infection: before or after transplant? 
To date, there is still no agreement on whether HCV infected patients with 
compensated cirrhosis on the transplant list should be treated for this infection prior to 
transplantation or immediately after transplantation, as these two approaches have not yet 
been compared prospectively in random trials using clinical endpoints 
40
. While some 
authors support that treating HCV infected patients selected for a hepatic transplant may 
improve liver function prior to transplantation and simultaneously prevent a subsequent 
graft infection, others argue that there are patients who don’t have the luxury of waiting 
any longer for transplantation, claiming that viral suppression is equally achieved with 
success immediately after transplantation due to the high efficacy and tolerability of 
current DAAs regimens, thus preventing the graft death and a potential HCV recurrence 
91,111,186,191
. 
1.13. Importance of resistance testing 
1.13.1. Management and importance of RASs in treatment 
failures 
Treatment monitoring should include several criteria in order to achieve a 
profound viral suppression with the least discomfort possible in the patient, such as the 
SVR rates and efficacy of the regimen, tolerability and potential adverse effects, the ease 
of use, and drug-drug interactions as well as consequent cross-resistances 
40
. 
The monitoring of treatment efficacy is based on measuring the HCV RNA levels 
at different time points via a sensitive and accurate test in order to ensure the consistency 
of results 
192,193
. Thusly, in HCV infected patients treated with a DAAs-based regimen, 
RNA levels or alternatively the core antigen, should be quantified immediately before 




 weeks to assess the adherence to treatment 
(optional), at the end of treatment at weeks 8, 12, 16 or 24 according to the duration of the 
selected regimen, and finally 12 and/or 24 weeks after the end of therapy in order to 
evaluate the SVR12 and/or SVR24, respectively 
40
.  
Fatigue, headaches, and nausea are often described as the most commonly 




LDV, SOF + VEL or SOF + DCV, when comparing to placebo. However, the proportion 
of patients with adverse effects whom permanently discontinue therapy accounts for less 
than 1%. In addition, contraindications to the use of ribavirin should always be checked 
since several side effects are often associated to its inclusion in treatment regimens, 




1.13.2. Clinical screening of baseline RASs: preventing 
therapeutic failures 
To date, routine HCV resistance testing prior to treatment is not recommended 
since access to reliable tests is still limited both financially and logistically, besides there 
is no consensus on the used techniques, its interpretation and/or notification criteria, and 
thus would seriously limit access to treatment options which can currently be optimized 
without the need of an additional resistance profile. Along these lines, baseline resistance 
testing is not recommended in TN patients, with the exception of SMV based regimens, 
combined regimens of EBV + GZP in patients infected with GT1a, any regimens 
submitted in patients infected with GT3 due to its known difficulty in virological 
responses, and additionally in risk behavior groups. In this way, resistance testing is 
instead recommended in therapeutic failures following a DAAs-based regimen in order to 
guide the best retreatment strategy. However, if a baseline resistance test both available, 
reliable and interpretable is performed (population sequencing or deep sequencing with 
15% and 1% cut-off limits, respectively), it should be directed for clinically relevant 
NS5A RASs (Table 1.4) involved in high level of resistance to NS5A inhibitors, and 
therefore the selected treatment with DAAs must include RBV and/or be extended in 
duration should any of these RASs be detected 
40,86,177
. 
1.13.3. Sequencing as a prognostic tool in drug resistance 
testing 
HCV sequencing manages to have a dual functionality as it not only allows for 
genotype assignment with a greater accuracy and discrimination than current commercial 




initiate treatment, and in this way helps physicians to select more appropriate therapeutic 
options for each patient, thus avoiding potential therapeutic failures thanks to an early 
detection of high resistance level RASs which could adversely affect viral suppression 
rates.  
The lack of detectability of RAVs is a worrying negative predictor factor which 
can mislead physicians in the selection of a given treatment, and is often related with the 
sensitivity of the sequencing technique, the viral load, and the reduced frequency of viral 
variants with RASs as well as a consequent rapid reversion to the wildtype strains due to 
the low viral fitness of certain RAVs 
70,149,160
. 
Several NGS platforms like SMRT deep sequencing and Illumina MiSeq are truly 
sensitive methods which allow for the detection of minority variants at levels below 1%, 
whereas Sanger sequencing can only succeed to reliably detect variants present above 20 
– 30% of the whole population 
194–196
. However, insight on the clinical relevance of 
detecting minority variants at levels below 15 – 20% is still both scarce and debatable, and 
as such Sanger population sequencing remains the gold standard over its high accuracy 
and reliability, given that a threshold of 20% appears to be sufficient in the detection of 
high risk RASs commonly associated to reduced SVR rates in DAAs-based regimens 
197
. 
1.13.4. Resistance testing pre-treatment initiation or 
post-treatment failure: an endless debate 
Current prices of DAAs regimens are very high and variable worldwide, thus most 
people can´t afford to be treated when government strategies don´t include a total 
coverage of treatment, which in return represents a risk to public health leading to the 
potential transmission of the virus, turning further away from the total eradication of 
HCV. In this way, baseline resistance analysis has been shown to be quite useful in the 
selection of increasingly specific regimens for each patient, and helps to achieve a 
complete viral suppression with high SVR rates countering the evolution of the virus in 
patients with persistent viral loads, as well as preventing future therapeutic failures 
associated with unnecessary high cost salvage DAAs 
149
. 
Authors supporting baseline resistance tests state that the prevalence of NS5A 
RASs in GT1 accounts for 6 – 25%, differing not only on HCV genotype but also 
geographically between countries 
155




reduced SVR rates, thus if detected prior to the initiation of treatment, baseline resistance 
testing would help to prevent potential therapeutic failures by further increasing current 
SVR rates and averting the emergence of high risk RAVs associated to inadequate 
regimens of DAAs, being particularly useful in patients whom did not respond to an 
previous regimen of pegIFN-α ± RBV, with or without an advanced progression of liver 
disease 
98,196
. Furthermore, there is a significant percentage of patients failing the selected 
treatment due to an incorrect genotype assignment 
122
, and since HCV genotyping is 
always required prior to treatment initiation, sequencing would constitute a far more 
accurate, reliable and discriminatory alternative to commercial genotyping assays, as it 
would simultaneously allow for a correct subtype assignment within a higher level of 
confidence, as well as provide an additional baseline resistance profile to assist 
physicians in guiding more appropriate treatment options based in DAAs specifically 




On the other side, authors against baseline resistance testing state that natural 
RASs do not appear to have a significant impact on therapeutic failures or reduced SVR 
rates to the extent of recommending it in TN patients, seeing that combinations of 
multiple high level RASs to DAAs are rarely observed in DAA-naïve patients 
174
, and 
argue that therapeutic failures are not avoided via resistance testing but rather through the 
selection of more potent pan-genotypic DAAs by physicians, since the impact of NS5A 
baseline RASs with a ˃ 100 fold-resistance can be reduced by simply increasing the 
duration of treatment with the inclusion of RBV 
157,158
. Moreover, these authors 
emphasize that therapeutic failures are primarily associated with poor adherence rates, 
and not so much to baseline RASs, and thus suggest that there should be a greater 
investment in adherence to therapeutic regimens by the patients, rather than investing in 
baseline resistance testing. 
But in the end, it all comes down to statistics and while some authors argue that 
with only a 1% rate of relapses, as well as more and more DAAs with a higher potency 
emerging in the pipeline, baseline resistance testing consequently becomes obsolete, they 
are actually being very optimistic as it has been demonstrated throughout the years that 
there is in fact at least a 5 – 10% rate of therapeutic failures systematically associated to 




1.14. Objectives and hypotheses 
 Our main goal was to study the profile of NS5 coding region RASs in DAA-naive 
genotype 1 HCV infected patients.  
 Additionally, three separate hypotheses were tested as to ascertain an association 
between treatment failure and: 
a. The non-discriminatory presence of baseline NS5 RASs; 
b. The baseline presence of NS5A, NS5B and/or NS5A + NS5B class RASs; 
c. The baseline presence of specific NS5 RASs. 
 A comparison between LiPA and Sanger population sequencing (BLAST and 
phylogenetic analysis) genotyping methods was also assessed as a way of availing the 
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2. Material and methods 
 
2.1. Samples 
 This study was approved by the Ethical Committee for Health of Centro 
Hospitalar de Lisboa Ocidental (CHLO) with the RNEC Registry Number: 
20170700050. 
 All sampling processing and analysis steps described in this chapter were 
performed at the Molecular Biology Laboratory of Egas Moniz Hospital, CHLO, Lisbon. 
A group of 81 clinical samples of plasma from DAA-naïve GT1a and GT1b infected 
patients selected to initiate treatment with DAAs between 2015 and 2017, were analyzed 
for baseline NS5 RASs. Eighteen samples corresponded to female patients (22%), while 
males were the predominant sex accounting for 63 samples (78%) (Table 2.1). The viral 





 HCV Test v2.0, from Roche Molecular Diagnostics (Basel, 
Switzerland), and all tested samples presented average high HCV RNA loads, ranging 
from 4,76 log10 to 7,44 log10 (Table 2.1). The HCV genotype had been previously 
determined using the VERSANT
®
 HCV Genotype 2.0 Assay Line Probe Assay (LiPA), 
from INNOGENETICS/Siemens Healthineers (Ghent, Belgium). Twenty-five samples 
corresponded to GT1b (31%), while GT1a was the predominant subtype accounting for 
56 HCV infected patients (69%). The IL28B gene polymorphism was additionally 
inquired in 76 of the 81 patients accounting for 58% (47/81), 28% (23/81) and 8% (6/81) 
patients with the CT, CC and TT polymorphisms, respectively. Of the 81 patients, 32% 
were HCV mono-infected (26/81), while 52% (42/81) and 5% (4/81) were co-infected 
with either HIV or HBV, respectively. Moreover, 11% (9/81) of the patients were 
simultaneously co-infected with HCV, HIV and HBV. Finally, 3 out of the 81 patients 
failed a treatment with DAAs (4%), and two patients showed an unknown treatment 
outcome status (2%) due to lack of adherence to the associated regimen or loss to 
follow-up evaluation before the SVR12 visit, resulting overall in a SVR rate of 94% 
(76/81) (Table 2.1). 
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Table 2.1 Demographic baseline characteristics of the HCV infected patients and treatment 
outcomes.  
 
2.2. HCV RNA extraction 
 HCV nucleic acids were extracted from 500µl of plasma previously conserved at 





 system v2.0 (with silica) (Boseind, Boxtel, The Netherlands), 
according to the manufacturer´s protocol.  
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2.3. PCR and sequencing primers design 
 In order to cover the NS5A and NS5B coding regions, each amplification reaction 
used two primers, one forward and one reverse, encompassing a length of approximately 
4800bp and 3700bp for the RT-PCR (outer PCR) and nested PCR (inner PCR), 
respectively (Supplementary Table 1). The in-house PCRs and sequencing protocols, 
including the primers for cDNA synthesis, nested PCR and Sanger sequencing were 
originally designed by Rute Marcelino (MSc, Medical Microbiology Department, IHMT, 
Lisbon). ClustalX v2.0 (http://www.clustal.org/clustal2/) and GENEDOC v2.7 
(http://www.psc.edu/biomed/genedoc/) softwares were used for the alignment and search 
of HCV genome consensus regions in reference sequences downloaded from the Los 
Alamos HCV database (https://hcv.lanl.gov/content/sequence/HCV/ToolsOutline.html), 
respectively. Oligonucleotides of 15 – 20bp were designed based after some of the 
consensus regions and tested upon standard compatibility features regarding GC content 
and melting temperature (Tm) using the OligoAnalyzer v3.1 online tool from 
INTEGRATED DNA TECHNOLOGIES (https://eu.idtdna.com/calc/analyzer). 
Degenerate primers were used for PCR and sequencing reactions in order to increase the 
detection ambiguity and reliability of a more diverse set of quasispecies variants. A total 
set of 10 primers (Supplementary Table 1), two of which being subtype specific, were 
selected to cover the NS5 coding region of GT1 HCV (Figure 2.1), in this way presenting 
the best results in the Sanger sequencing protocol optimization. However, since the 3'-end 
of the NS5B gene is a poly-U (U/C) region highly composed of hairpins and secondary 
structures which obstruct the annealing process, the associated FW6 sequencing primer 
(Supplementary Table 1) was in this way unable to completely hybridize during the 
sequencing reactions, and three important amino acid positions (A553, G554, and S556) 
associated with resistance to dasabuvir were consequently left uncovered. Moreover, 12 
additionally tested back-up sequencing primers were saved for later use if necessary 
(Supplementary Table 1). All primers were synthesized by Invitrogen/ALFAGENE 
(Carcavelos, Portugal), with the exception of RV9 which was manufactured by TIB 
MOLBIOL (Eresburgstraße, Berlin, Germany). 
 




Figure 2.1 Sequencing primers considered to cover the entire NS5 coding region of HCV. Primers in red are anti-sense and primers in blue are sense. 
Continuous lines correspond to the main primers used to cover the NS5 region, whereas dashed lines represent back-up primers to use if necessary. 
Numbers in parenthesis represent the location (bp) in the HCV genome using the reference H77. 
A1
Primers for GT1a only. 
B1
Primers for GT1b only.
FW2PCR (5386 - 5403) 
RV1 (6493-6509) 
FW1 (6118-6134) 
1aFW8 (6433-6450)A RV4 (7936-7955) 
RV6 (7606-7619) 
FW5 (8128-8147) 
RV9 (8083 - 8102) RV2PCR (9055 - 9073) 










FW2 (7093 - 7107) 
Lenght (bp) 500 1000 1500 2000 2500 3000 3500 
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2.4. cDNA-synthesis and nested PCR 
 A reverse transcription in-house PCR was immediately performed after RNA 
extraction to guarantee the viability of the HCV nucleic acids and the success of the 
amplification process as well as the quality of HCV sequences and consequently of the 
sequencing chromatogram, since the genomic structure of RNA tends to be very unstable 
and continuous sampling frosting and defrosting should be avoided. Along these lines, 
HCV RNA was reverse transcribed using the OneStep RT-PCR Kit from QIAGEN, and 
this first round of amplification (outer PCR) was performed under the following final 
conditions (Table 2.2): OneStep RT-PCR Buffer (1X), 2,5µl of OneStep RT-PCR 
Enzyme Mix (Supplementary Table 2), dNTPs Mix (400µM each), 0,5µM sense primer 
FW1, 0,5µM anti-sense primer RV1, 10U/reaction of protector RNase inhibitor 
(Supplementary Table 2), 10µl of template RNA, and RNase-Free water (Supplementary 
Table 2) to make up a final reaction volume of 50µl. Afterwards, the remaining extracted 
RNA templates were conserved at -80ºC. 
Table 2.2 RT-PCR (outer PCR) mix reagents and associated volumes calculated accordingly to 
the reaction concentrations (final concentrations), using the Qiagen One Step RT-PCR Kit. Blank 
spaces represent expendable or unobtainable information.  
 
* Sold separately from the Qiagen One Step RT-PCR Kit.   
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 LifeECO thermal cycler by Hangzhou BIOER Technology or GeneAmp
®
 PCR 
System 9700 by Applied Biosystems were used for the amplification process, and cycling 
conditions were as follows (Table 2.3): a reverse transcription step at 45ºC for 30min, a 
HotStarTaq polymerase activation step at 95ºC for 15min to initiate PCR, a touchdown 
PCR step of 16 cycles of 10sec at 94ºC (denaturation step), 45sec at 63ºC with -1ºC/cycle 
(annealing step), and 5min at 68ºC (extension step), a final PCR step of 30 cycles of 10sec 
at 94ºC, 45sec at 48ºC, and 5min at 68ºC with a time increment of +3sec/cycle, and a final 
elongation step of 10min at 68ºC. The reaction was then cooled down to 4ºC, and 
RT-PCR products were stored at -20ºC or immediately used in the nested PCR step.  
Table 2.3 RT-PCR (outer PCR) cycling conditions.  
 
* Increments of +3sec/cycle. 
 Two microliters of the RT-PCR reaction product were amplified in a second 
in-house nested PCR divided in two mixes as recommended by the Expand High Fidelity 
PCR System kit (Roche), under the following conditions (Table 2.4): Mix 1 [dNTPs mix 
(200µM each), 0,3µM sense primer FW2, 0,3µM anti-sense primer RV2, and 
RNase-Free water to make up a mix volume of 23µl] (Supplementary Table 2) and Mix 2 
[Expand High Fidelity Buffer (1X) without MgCl2, 0,4% DMSO, 3mM MgCl2, 
3U/reaction of Expand High Fidelity Enzyme mix, and RNase-Free water to make up a 
mix volume of 25µl] (Supplementary Table 2). Finally, 2µl of template cDNA were 
mixed with 23µl of Mix 1, following the addition of 25µl of Mix 2 to make a final 
reaction volume of 50µl for each sample.   
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Table 2.4 Nested PCR (inner PCR) mix reagents and associated volumes calculated accordingly 
to the reaction concentrations (final concentrations), using the Expand High Fidelity PCR System 
from Roche. Blank spaces represent expendable or unobtainable information.    
 
* Sold separately from the Expand High Fidelity PCR System.  
 LifeECO thermal cycler (Hangzhou BIOER Technology) or GeneAmp
®
 PCR 
System 9700 (Applied Biosystems) were used for the amplification process, and cycling 
conditions were as follows (Table 2.5): a denaturation step at 95ºC for 3min, a touchdown 
PCR step of 16 cycles of 15sec at 94ºC, 30sec at 60ºC with -1ºC/cycle, and 3min at 68ºC, 
a final PCR step of 30 cycles of 15sec at 94ºC, 30sec at 45ºC, and 3min at 68ºC with a 
time increment of +5sec/cycle, and a final elongation step of 7min at 68ºC. The reaction 
was then cooled down to 4ºC, and nested PCR products were stored at -20ºC. 
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Table 2.5 Nested PCR (inner PCR) cycling conditions.  
 
* Increments of +5sec/cycle.  
 
2.5. Gel electrophoresis and purification of PCR 
products 
 Analysis of the PCR products was done via agarose gel electrophoresis. Seven 
microliters of PCR product were mixed with 3µl of DNA loading buffer and then run on a 
1% agarose gel incorporated with RedSafe
TM
 Nucleic Acid Staining Solution 
(Supplementary Table 2), at 100V. Five microliters of 1 kb Plus DNA Ladder 
(Supplementary Table 2) were adjacently run with the PCR products to ascertain the 
length of the associated fragments, namely 4800bp and 3700bp for the RT-PCR and 
nested PCR, respectively. When positive, the nested PCR products were purified using 
the PCR Cleanup Kit protocol from Abbott Molecular Inc. by adding the respective 
ExoSAP cleanup reagent (Supplementary Table 2) to the nested PCR product in a 
proportion of 1:4, under the following cycling conditions (Table 2.6): 30min at 37ºC 
followed by 15min at 80ºC.  
Table 2.6 cDNA purification cycling conditions.  
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 The reaction was then cooled down to 4ºC, and dilutions from 1:2 to 1:10 of the 
purified PCR products were followed if necessary, accordingly to the intensity of the 
electrophoresis bands i.e. the more intense the band the higher the dilution. Purified 
nested PCR products were stored at -20ºC.  
2.6. Sequencing and resistance profile analysis 
 Sanger population sequencing (15% cut-off value) on 3130xl ABI PRISM 
Genetic Analyzer by HITACHI/ThermoFisher Scientific (Tokyo, Japan) was performed 
for the purified nested PCR products, using a BigDye
TM
 Terminator v3.1 Cycle 
Sequencing kit (Supplementary Table 2) and a total of 9 primers per GT1a or GT1b in 
order to cover the entire NS5 coding region. The sequencing process was separated in two 
sets of mix reactions per primer, one for genomic regions of difficult hybridization by the 
designed sequencing primers (Reaction Mix A) and other for regions of easy 
hybridization (Reaction Mix B), and performed under the following final concentration 
conditions: Reaction Mix A [BigDye
TM
 Sequencing Buffer (0,75X), 2µl of BigDye
TM
 
Terminator 3.1 Reaction Mix, 1µl of primers (5µM stock solution) RV4, FW6 and RV9 
separately per reaction, 1µl of purified template cDNA, and RNase-Free water to make 
up a reaction volume of 20µl] (Table 2.7) and Reaction Mix B [BigDye
TM
 Sequencing 
Buffer (0,75X), 1µl of BigDye
TM
 Terminator 3.1 Reaction Mix, 1µl of primers (5µM 
stock solution) RV2PCR, FW1, FW4, FW5, RV6, 1bRV7 and 1aFW8, separately per 
reaction, 1µl of purified template cDNA, and RNase-Free water to make up a reaction 
volume of 10µl] (Table 2.8). GeneAmp
®
 PCR System 9700 (Applied Biosystems) was 
used for the sequencing reaction, and cycling conditions were as follows (Table 2.9): a 
denaturation step at 96ºC for 5min, 35 cycles of 5sec at 94ºC, 10sec at 50ºC, and 4min at 
60ºC, followed by a cool down to 4ºC. Back-up sequencing primers, were also available 
to use accordingly to the Reaction Mix A, if the main primers were not successful in 
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Table 2.7 Sanger population sequencing reaction mix A reagents and associated volumes 
calculated accordingly to the reaction concentrations (final concentrations), adapted for 3130xl 
ABI PRISM Genetic Analyzer. Blank spaces represent expendable or unobtainable information.    
*
1
RV4, FW6 and RV9, separately per reaction. If needed, apply same reaction conditions to back-up 
primers: FW2PCR, RV1, FW2, RV2, FW3, RV3, RV5, FW7, 1bRV8, 1aFW9, 1aFW10 and 1bFW11.  
Table 2.8 Sanger population sequencing reaction mix B reagents and associated volumes 
calculated accordingly to the reaction concentrations (final concentrations), adapted for 3130xl 
ABI PRISM Genetic Analyzer. Blank spaces represent expendable or unobtainable information.    
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Table 2.9 Sanger population sequencing cycling conditions for reaction mixes A and B, adapted 
for 3130xl ABI PRISM Genetic Analyzer. 
 
 A purification of the sequencing reaction products was needed before running on 
the sequencing equipment, and started by distributing 52µl of sodium acetate buffer 
diluted in 100% ethanol per MicroAmp® reaction plate well (Supplementary Table 2), 
followed by a strong centrifugation at 3300rpm for 20 minutes. The reaction plate was 
then inverted and softly centrifuged at 900rpm for one minute to remove excess waste. 
Subsequently, 150µl of 70% ethanol were distributed per reaction well, followed by a 
strong centrifugation at 3300rpm for 5 minutes, and the reaction plate was again inverted 
and softly centrifuged at 900rpm for one minute. The reaction plate was left to dry for 2 
minutes, and 20µl of formamide were added per MicroAmp® reaction plate well setting 
up 16-capillary complete runs. Lastly, sequencing reaction plates were run on the 3130xl 
ABI PRISM Genetic Analyzer and nucleotide sequence chromatograms for each sample 
were obtained.  
 The primers nucleotide sequences for each sample were joined in a single contig 
and edited using ChromasPro

 software v1.7.6. (Technelysium Pty Ltd). Finally, 
complete nucleotide sequences were converted to FASTA format and analyzed online in  
Geno2pheno [HCV] v0.92 (http://hcv.geno2pheno.org/), providing the baseline 
resistance analysis profile for each patient. All sequences obtained in this study, were 
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2.7. Phylogenetic analysis for HCV genotyping 
 A reference alignment of 195 Okamoto region consensus sequences ranging from 
genotypes 1 to 7, specific for the purpose of HCV genotyping, were downloaded from the 
Los Alamos HCV sequence alignments database 
(https://hcv.lanl.gov/content/sequence/NEWALIGN/align.html). Those were aligned 
together with the 81 consensus sequences obtained by Sanger sequencing as described in 
this study, using ClustalX software v2.0. The obtained alignment was edited using 
GENEDOC software v2.7, and phylogenetic trees were constructed using MEGA v6 
software (http://www.megasoftware.net/). Neighbor-Joining and Maximum-Likelihood 
statistical methods were used for tree building, both following the Kimura 2-parameter 
substitution model and Gamma distributed rates among sites. Additionally, NJ/BioNJ 
tree inference option was selected for the maximum-likelihood algorithm. Ten thousand 
bootstrap replicates were performed for both algorithms in order to evaluate the 
robustness of the tree. The resulting phylogenetic trees were visualized and esthetically 
edited using FigTree software v1.4.3 (http://tree.bio.ed.ac.uk/software/figtree/).  
2.8. Statistical analysis 




 Statistics v19 (SPSS Inc., 
Chicago, Illinois, USA) and Microsoft Excel. The association between the presence of 
NS5 coding region RASs and continuous variables was analyzed using the 
Mann–Whitney U or Kruskal-Wallis H nonparametric tests, whereas categorical 
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3. Results and discussion 
 
3.1. Comparison between HCV genotyping methods 
 The resistance profile analysis via sequencing conveniently provides a quick way 
of HCV genotyping through an online nucleotide BLAST. In this way, a thorough 
comparison between LiPA and Sanger population sequencing (BLAST and phylogenetic 
analysis) genotyping methods was conceived as an additional way of exploring the many 
uses that sequencing is capable of providing, as well as to validate the best method 
undertaken.  
 Overall, the subtype assignment of all 81 HCV sequences obtained in this study 
revealed a total of seven discrepancies (Table 3.1), of which six were due to incomplete, 
ambiguous or inconclusive LiPA genotyping and one due to rather wrong genotype 
attribution by LiPA.  
 Phylogenetic analysis of the obtained GT1 HCV sequences using the Okamoto 
region was successful for subtype assignment, being supported by bootstrap values well 
above 70% when based on the Neighbor-Joining method following the Kimura 
2-parameter substitution model, namely 91% and 90% for GT1a and GT1b clades (Figure 
3.1), respectively. These bootstrap values are further supported by a second more 
rigorous phylogenetic tree based on the Maximum-Likelihood method following the 
Kimura 2-parameter substitution model, namely 84% and 89% for GT1a and GT1b 
clades (Figure 3.2), respectively, still much confidently higher than 70%. Furthermore, 
although bootstrap values for genotype 1 attribution per se, were slightly under 70% for 
both phylogenetic trees (69% and 65% for Neighbor-Joining and Maximum-Likelihood 
methods, respectively), all 81 GT1 HCV sequences were indubitably genotyped and 
subtyped, seeing that the previously described GT1a and GT1b clades bootstrap values 
were much higher than 70% for both phylogenetic analysis methods.  
 Finally, even though there were no genotype attribution discrepancies in any of 
the relapsing patients on this study, an incorrect genotype assignment by the current 
commercial genotyping assays stills remains a significant factor in the treatment failure 
of HCV infected patients 
122
.  
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Table 3.1 Genotype assignment of all 81 HCV infected patients. Genotype attribution 
discrepancies between Inno-LiPA genotyping and Sanger sequencing are highlighted in yellow. 
In sequencing genotyping, the obtained HCV sequences were submitted to hcv.geno2pheno.org/ 
for both resistance and genotyping profiling, following a nucleotide BLAST 
(blast.ncbi.nlm.nih.gov/) to ascertain a resemblance between the query sequences and the NCBI 
database DNA sequences. A posterior phylogenetic analysis based on the Neighbor-Joining and 
Maximum-Likelihod methods was conducted on the obtained sequences, for a subtype 
assignment with higher accuracy.  
 
  



























Figure 3.1 Phylogenetic consensus trees of the obtained GT1 HCV sequences, based on the 
Neighbor-Joining method using MEGA v6: A, Radial layout tree view of all HCV genotypes; B, 
Rectangular layout tree view of all HCV genotypes; C, Genotype 1 clade with GT1a and GT1b 
obtained sequences marked in blue and green, respectively. Ten thousand bootstrap replicates 
were performed to evaluate the robustness of the topology, and main clades bootstrap values are 
indicated beside of each node. The genetic distance scale bar is at the bottom of each figure, 
indicating the number of nucleotide substitutions per site along each lineage.  
C 











Figure 3.2 Phylogenetic consensus trees of the obtained GT1 HCV sequences, based on the 
Maximum-Likelihood method using MEGA v6: A, Radial layout tree view of all HCV genotypes; B, 
Rectangular layout tree view of all HCV genotypes; C, Genotype 1 clade with GT1a and GT1b 
obtained sequences marked in blue and green, respectively. Ten thousand bootstrap replicates 
were performed to evaluate the robustness of the topology, and main clades bootstrap values are 
indicated beside of each node. The genetic distance scale bar is at the bottom of each figure, 
indicating the number of nucleotide substitutions per site along each lineage.  
C 
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3.2. Statistical analysis 
 Using a confidence level of 95%, statistical analysis indicated that treatment 
failure was not significantly associated with either the class of NS5 RASs (p = 0.549) or 
the mere non-discriminatory presence of baseline NS5 RASs (p = 0.232). However, a very 
strong statistical significant association was found between treatment failure and the 
presence of specific baseline NS5 RASs, namely Y93C/H (p = 0.04, with a Phi and 
Cramer´s V strength of association effect size of 0.376).  
 An additional association between the presence of baseline NS5 RASs and several 
extra variables such as the viral load right before treatment initiation, age, sex, the IL28B 
polymorphism, co-infection status and HCV genotype, was parallelly sought over as to 
find a connection to other relevant variables common in the clinical practice of HCV 
infection besides treatment failure. Overall, few significant associations were found 
between the presence of NS5 RASs and any of these variables, nonetheless HCV 
genotype stood out by revealing a statistical significant association to the 
non-discriminatory presence of baseline NS5 RASs (p = 0.001), namely with GT1b being 
the strongest predictor of this association, as well as to the class of NS5 RASs (p = 0.000), 
namely with GT1b and NS5B RASs being the strongest predictors of association. 
Moreover, HCV genotype also exhibited a significant association to the presence of 
specific baseline NS5 RASs, namely A92E/T (p = 0.007), L159F (p = 0.000), C316N 
(p=0.000), and C451I/Y (p=0.007), being GT1b ever the strongest predictor of these 
associations. Finally, the IL28B polymorphism revealed a statistical significant 
association to the non-discriminatory presence of baseline NS5 RASs (p  = 0.041), namely 
with IL28B CC polymorphism being the strongest predictor of association, as well as to 
the presence of specific baseline NS5 RASs, namely H58C/P/S (p = 0.02) and the major 
Y93C/H mutation (p1=10.026), with the IL28B TT and CC polymorphisms being the 
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3.3. Resistance profile analysis  
3.3.1. Prevalence of NS5 RASs and treatment outcome 
 Amongst all genotype 1 infected patients, 38,3% (31/81) presented NS5 RASs at 
baseline, with NS5A class RASs showing the highest prevalence, followed by NS5B 
RASs and the combined NS5A + NS5B RASs, namely 23,5% (19/81), 9,9% (8/81) and 
4,9% (4/81), respectively (Figure 3.3). However, the prevalence of NS5A and NS5B 
RASs would rise up to 28,4% (23/81) and 14,8% (12/81), respectively, when not 
considering separately the dual-class RASs. In a study from 2016 analyzing data from 
phase II/III trials of 2108 GT1 infected patients in order to evaluate the effects of baseline 
NS3, NS5A and NS5B RASs on the response to a SOF/LDV based regimen, up to 16% 
(338/2108) and 2,5% (43/1692) of patients had detectable NS5A and NS5B RASs, 
respectively 
158
.   
 
Figure 3.3 Baseline prevalence of NS5 RASs in all GT1 HCV infected patients. Substitution 
analyses were conducted on Sanger sequencing data with a 15% cut-off limit. Dual-class RASs 
are assigned as NS5A + NS5B RASs. 
 About 27% (15/56) of the GT1a infected patients presented NS5 RASs, although 
only NS5A class, comparing to a much higher percentage of NS5 RASs in the GT1b 
infected patients accounting for 64% (16/25), with NS5B RASs prevailing at 32% (8/25) 
followed by NS5A and dual-class RASs both at 16% (4/25) (Figure 3.4). However, from 
another point of view, the GT1b patients showed a higher prevalence of NS5A RASs than 
for GT1a, namely 32% (8/25), when not considering separately the dual-class RASs. In 
two studies comparing the effect of baseline NS5A RASs on a SOF/LDV based regimen 
198,199
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GT1a, namely 25,2% (52/206) and 17,6% (25/142) vs. 13,2% (40/303) and 7,1% 
(12/170), for each case study respectively, but still insignificant on SVR rates, except for 
treatment-experienced patients with decompensated cirrhosis infected with GT1a HCV in 
which these RASs conferred a high fold resistance (˃ 100x). 
 
Figure 3.4 Percentage of HCV infected patients with NS5 RASs, according to HCV subtype. 
Substitution analyses were conducted on Sanger sequencing data with a 15% cut-off limit. 
Dual-class RASs are assigned as NS5A + NS5B RASs. 
 NS5A constitutes the most important genomic region considered for the screening 
of associated RASs. As such, 19,8% (16/81) of all 81 GT1 infected patients showed at 
least one RAS that conferred more than 100-fold resistance to ledipasvir (Q30H/R, 
L31M, and/or Y93C/H), namely 21,4% (12/56) and 16% (4/25) of GT1a and GT1b 
infected patients, respectively, and have also been described in several clinical trials as 
the most frequently encountered clinically relevant baseline NS5A RASs in GT1 HCV 
40,76,98,152,154–156
. Along these lines, all regimens based in NS5A inhibitors should include 
a NI with a high genetic barrier to resistance, currently sofosbuvir, since this combination 
has been shown to elicit a profound viral suppression 
200,201
 as well as higher SVR rates 
when treatment duration is extended to 24 weeks with or without ribavirin. This data is 
further supported from deep sequencing analysis of baseline NS5A RASs in 276 GT1 
infected patients, which showed a prevalence of 21,4% (59/276) of high level NS5A 
RASs conferring resistance to ledipasvir 
202
, though a contemporary study described a 
much lower prevalence, as 11,5% (102/887) of treatment-naive GT1 infected patients had 
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 Dual-class RASs were only observed in 4 GT1b infected patients, whereas 
combined intra-class RASs were detected in 4 GT1a patients concerning the NS5A gene 
(Q30H + Y93H), and then in one and six GT1b patients for the NS5A (A92T + Y93H) and 
NS5B (L159F + C316N and L159F + C316N + C451Y) regions, respectively (Figure 3.5). 
 
Figure 3.5 Baseline prevalence of detected NS5 RASs combinations within GT1 infected patients 
with RASs. NS5A, NS5B and dual-class RASs are viewed in variations of blue, green and orange, 
respectively. Substitution analyses were conducted on Sanger sequencing data with a 15% 
cut-off limit. 
 Baseline resistance testing of the NS5 coding region showed that the efficacy of 
SOF and NS5A inhibitors, mainly LDV, was not compromised in most patients whom 
showed a natural presence of RASs before treatment initiation, since NS5 RASs were 
present in 38,2% of patients who achieved a SVR, with 22,4% (17/76), 10,5% (8/76), and 
5,3% (4/76) corresponding to NS5A, NS5B and dual-class RASs, respectively (Figure 
3.6). Nonetheless, 66,7% (2/3) of the relapsing patients presented NS5A class only RASs, 
as the combined Q30H + Y93H mutations, causing high level resistance to all NS5A 
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failed a treatment with SOF/LDV for 12 weeks. However, another relapsing HIV/HCV 
GT1a co-infected patient whom also failed the same therapeutic settings previously 
described, showed no NS5 RASs at baseline. Furthermore, an isolated Y93H mutation 
was also detected at baseline in one GT1b mono-infected patient experiencing virological 
relapse.  
 
Figure 3.6 Percentage of HCV infected patients with NS5 RASs, according to treatment outcome 
status. Substitution analyses were conducted on Sanger sequencing data with a 15% cut-off limit. 
Dual-class RASs are assigned as NS5A + NS5B RASs. 
 Even though the Y93H mutation showed a significant effect on treatment outcome 
(p = 0.04) being detected as a dominant substitution for the two patients who did not 
achieve SVR12 with NS5A RASs, most patients with at least one NS5A RAS conferring 
˃ 100-fold resistance to ledipasvir still achieved SVR12. This data is further corroborated 
from a recent study in which the reduction in SVR rates of 2108 GT1 infected patients 
who received a regimen of SOF + LDV, appeared to be driven predominantly by patients 
with NS5A RASs, namely with Y93H being detected as a dominant substitution, 
although the general presence of baseline NS5A and NS5B RASs had showed no 
significant impact on treatment outcome, with SVR rates greater than 91% 
158
. Moreover, 
a deep sequencing analysis of baseline NS5A RASs in 276 and 32 patients infected with 
GT1 and GT4 HCV, respectively, showed that all patients who failed to achieve SVR12 
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Finally, no RASs were detected in the two GT1a infected patients with an unknown 
treatment outcome. 
 Overall, 93,5% (29/31) of patients with baseline NS5 RASs achieved SVR12, of 
which 54,8% (17/31), 25,8% (8/31) and 12,9% (4/31) corresponded to NS5A, NS5B and 
NS5A + NS5B class RASs, respectively, comparing to only two patients (6,5%) whom 
experienced virological failure by carrying NS5A RASs (Figure 3.7).  
 
Figure 3.7 Baseline prevalence of NS5 RASs in GT1 HCV infected patients, according to 
treatment outcome status. Substitution analyses were conducted on Sanger sequencing data 
with a 15% cut-off limit. Dual-class RASs are assigned as NS5A + NS5B RASs. 
3.3.2. Prevalence of NS5 RASs and environmental factors 
 The prevalence of NS5 RASs was amazingly balanced between the male and 
female sex, namely 38,1% (24/63) vs. 38,9% (7/18), respectively (Figure 3.8). Regarding 
the IL28B gene polymorphism, patients exhibiting the IL28B CC polymorphism showed 
the highest prevalence of NS5 RASs, followed by the IL28B TT and CT polymorphisms, 
namely 60,9% (14/23), 50% (3/6) and 27,7% (13/47), respectively (Figure 3.9). 
Furthermore, up to 20% of patients with an unknown IL28B polymorphism presented 
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Figure 3.8 Percentage of HCV infected patients with NS5 RASs, according to sex. Substitution 
analyses were conducted on Sanger sequencing data with a 15% cut-off limit. Dual-class RASs 
are assigned as NS5A + NS5B RASs. 
 
 
Figure 3.9 Percentage of HCV infected patients with NS5 RASs, according to the IL28B gene 
polymorphism. Substitution analyses were conducted on Sanger sequencing data with a 15% 
cut-off limit. Dual-class RASs are assigned as NS5A + NS5B RASs. 
 According to the monoinfection and co-infection status, HCV mono-infected 
patients showed the highest prevalence of NS5 RASs, followed by HCV/HIV/HBV 
co-infected, HCV/HIV co-infected and HCV/HBV co-infected patients, namely 46,2% 
(12/26), 44,4% (4/9), 33,3% (14/42) and 25% (1/4), respectively (Figure 3.10). 
Additionally, of the 31 GT1 HCV infected patients whom presented NS5 RASs at 











































NS5 RASs NS5A RASs NS5B RASs NS5A+NS5B RASs 
Results and discussion 
61 
 
Figure 3.10 Percentage of HCV infected patients with NS5 RASs, according to the monoinfection 
and co-infection profiles. Substitution analyses were conducted on Sanger sequencing data with 
a 15% cut-off limit. Dual-class RASs are assigned as NS5A + NS5B RASs. 
3.3.3. Prevalence of NS5A specific RASs 
 Major NS5A RASs were detected in 23,2% (13/56) of GT1a infected patients 
(M28V, Q30H/R, L31M and/or Y93C/H) and in 16% (4/25) of GT1b infected patients 
(L31M and Y93H), although minor NS5A RASs were also detected in 3,6% (2/56) of 
GT1a patients (H58C/P) and in 20% (5/25) of GT1b patients (L28M, H58S and A92E/T).  
 The most commonly detected NS5A RAS was Y93C/H with a baseline 
prevalence of 9,9% (8/81) in all GT1 infected patients, followed by L31M and Q30H/R 
with a prevalence of 8,6% (7/81) and 6,2% (5/81), respectively (Figure 3.11). Moreover, 
Y93C/H showed a higher prevalence in GT1b patients than in GT1a, namely 12% (3/25) 
vs. 8,9% (5/56), respectively. The baseline Y93C/H mutation largely accounted for 
25,8% (8/31) of all patients carrying RASs, followed by L31M and Q30H/R, with 22,6% 
(7/31) and 16,1% (5/31), respectively (Figure 3.12). A 2015 analysis of more than 3000 
GT1 NS5A sequences has demonstrated a higher baseline prevalence of the Y93C/H/N 
mutation, especially in GT1b, being mostly found in South Korea (15,3%) followed by 
Japan (13,9%) and Spain (13,6%), whereas in GT1a the baseline Q30E/H/R mutation was 
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Italy (4,9%) followed by France (4,8%) and New Zealand (3,9%) 
155
. Furthermore, an 
analysis from the same year of NS5A sequences in 132 Japanese GT1b HCV infected 
patients, established that baseline NS5A RASs are common in treatment-naive patients 
infected with GT1b, demonstrating an even higher prevalence of the Y93H mutation, 
namely 25% (32/132) 
195
. 
3.3.4. Prevalence of NS5B specific RASs 
 NS5B RASs accounted for 14,8% (12/81) of GT1 HCV infected patients when not 
considering separately the dual-class RASs, and were only detected in GT1b patients, all 
of which achieved SVR12. Furthermore, these were mainly represented by the C316N 
mutation, accounting for 40% (10/25) of GT1b infected patients, and showing the highest 
prevalence amongst all patients with baseline NS5 RASs, namely 32,3% (10/31) (Figure 
3.12). The major S282T mutation, causing high level resistance to sofosbuvir was never 
detected, however, the baseline L159F mutation which confers a reduced susceptibility to 
this drug, was detected in 24% (6/25) of GT1b infected patients, and in 19,4% (6/31) of 
all patients carrying NS5 RASs. Along these lines, patients treated with regimens based 
on NS5B polymerase inhibitors, particularly NIs, tend to exhibit a low prevalence of 
baseline RASs 
174
, but when detected the most frequently encountered appear to be 
L159F, C316N/Y, L320F, V321A, M414T, and S556G 
76,98,102,203–205
.  
 Dasabuvir on the other hand possesses a low genetic barrier to resistance, as the 
associated C316N mutation tends to achieve a substantial baseline prevalence of 10 – 
36% in GT1b infected patients 
98,206,207
. Moreover, an analysis of more than 7800 NS5A 
and NS5B sequences from HCV infected patients across 22 countries showed 
prevalences of up to 34% for the L159F mutation in GT1b infected patients 
155
. Finally, 
several studies analyzing the natural presence of NS5B RASs equally refute an associated 
significant impact on SVR12 rates 
152,208
, which further strengthens the obtained data. 




Figure 3.11 Baseline prevalence of specific NS5 RASs in all 81 HCV infected patients by subtype. Substitution analyses were conducted on Sanger 
sequencing data with a 15% cut-off limit. Dual-class RASs are assigned as NS5A + NS5B RASs. 
 
 
Figure 3.12 Baseline prevalence of specific NS5 RASs within GT1 infected patients with RASs. Substitution analyses were conducted on Sanger 
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 According to the WHO Global baselines and coverage targets 
209
, there is an 
estimated 90% reduction of HCV and HBV infections and related deaths up to 2030. 
However, HCV treatment coverage worldwide is still below 10%, emphasizing the need 
of considerable HCV and HBV treatment scale-up to reach the WHO HCV and HBV 
treatment coverage targets prior to 2030 
209
. In this way, the strategies for HCV 
elimination ought to be fully complied and mainly focused on a Test & Treat routine in 
which rapid point-of-care testing should be progressively more implemented in the 
clinical practice, as well as on Prevention & Awareness services specially directed to 
major risk groups. Additionally, research should be promoted for the development of a 
HCV vaccine as well as to the implementation of a HCV prophylaxis directed in 
particular for risk groups such as PWID just like what was recently successfully done 
with PrEP (Pre-Exposure Prophylaxis) for HIV 
210–213
, as these strategies would be an 
asset in achieving the treatment coverage targets up to 2030, thus becoming a step closer 
to HCV global elimination in populations of both HCV mono-infected and co-infected 
patients with HIV and/or HBV.  
 HCV sequencing is constantly improving and becoming more widely available. In 
summary, baseline sequencing can help in the selection of an optimal therapy, especially 
in difficult-to-treat patients, and phylogenetic analysis came as great aid to this study over 
its rigorous methodology of genotyping in comparison to commercially available assays 
like LiPA, which consequently corrected several misclassified samples. In addition, 
phylogenetic analysis comes quite useful in the clinical practice as it can be used to 
distinguish relapses from re-infections, as well as to find out how transmission networks 
work in a more epidemiological setting. 
 Failure to completely sequence the NS5B region was explained by virtue of the 
3'-end of the HCV genome being a poly-U (U/C) region highly composed of hairpins and 
secondary structures, which consequently left uncovered three important amino acid 
positions (A553, G554, and S556) associated with resistance to dasabuvir. Consequently, 
a potential solution could reside in improving both RT-PCR and nested PCR primers in 
order to replicate a relatively longer fragment that contains all NS5A and NS5B amino 




constitute a solution to this problem since some platforms can bypass the use of 
sequencing primers, resulting in a potentially cheaper resistance testing and a much more 
revealing methodology in terms of mutations due to the 1% cut-off limit.  
 The obtained data supports the usefulness of resistance testing prior to treatment 
initiation, thus preventing relapses associated to the presence of baseline RASs, as a 
statistical significant association was found between treatment failure and the baseline 
presence of specific NS5 RASs, namely Y93C/H (p = 0.04). With this in mind, an 
interesting recommendation to take into account would be to implement a protocol of 
baseline resistance testing directed only for the clinically relevant Y93 amino acid 
position of the NS5A gene, since all other NS5 RASs, excluding the rare S282T mutation 
which was not detected, do not seem to have a significant impact on treatment outcome 
when on sofosbuvir plus NS5A inhibitors based regimens. However, this reduced 
sampling can constitute a limiting factor, since it may underestimate the statistical 




 In conclusion, baseline NS5 RASs seem to have minimal effects on patient 
responses to sofosbuvir plus NS5A inhibitors (LDV, DCV, VEL) based therapies, having 
been well established through cumulative research data that when baseline NS5A RASs 
in particular do have effects, they could be largely over-come by extending treatment 
duration and/or through treatment intensification with the addition of RBV, thus 
drastically reducing the impact of NS5A baseline RASs 
145,149,208,215,216
. Additionally, the 
cost-effectiveness of baseline resistance testing was accessed in a recent paper describing 
that the inquiry of baseline NS5A RASs prior to a treatment with EBR/GZR is indeed a 
cost-effective measure resulting in more QALYs (quality-adjusted life years) among 
GT1a treatment-naive or treatment-experienced patients, when comparing to a treatment 
with EBR/GZR without baseline resistance testing, and LDV/SOF or 3D based regimens, 




 On a final note, the importance of total adherence to the treatment should always 
be encouraged and insisted upon in an elucidative way by physicians in order to prevent 
potential relapses in patients, since lack of adherence to treatment is perhaps the main 
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6. Supplementary material  
Supplementary Table 1 Primers for RT-PCR (outer PCR), nested PCR (inner PCR) and 
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Supplementary Table 2 List of materials and reagents used along the sampling processing, from 
the HCV RNA extraction to the sequencing final step.    
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